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Abstract Plant stanol esters not only lower low density
lipoprotein cholesterol but also have previously been
shown to lower serum triacylglycerol (TAG) concentra-
tions, especially in subjects with elevated TAG concen-
trations. To ﬁnd a possible explanation, we explored
changes in serum lipoprotein proﬁles, as measured with
nuclear magnetic resonance. For this, serum samples from
two parallel-designed controlled studies were evaluated
before and 8 weeks after the consumption of plant stanol
esters. In the ﬁrst study, dyslipidemic metabolic syndrome
subjects participated and in the second study normolipi-
demic subjects. In metabolic syndrome subjects, plant
stanol esters lowered concentrations of large ([60 nm) and
medium (35–60 nm) VLDL particles as compared to con-
trols. In normolipidemic subjects, the serum concentration
of large VLDL-1 particles was also lowered, although less
pronounced. Based on these ﬁndings, we hypothesize that
the effect of plant stanol esters on serum TAG concentra-
tions origins from a lowered hepatic production of large
TAG-rich VLDL-1 particles.
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TAG Triacylglycerol
LDL Low density lipoprotein
HDL High density lipoprotein
LPL Lipoprotein lipase
CETP Cholesterol ester transfer protein
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Introduction
It is well established that plant stanol esters lower intestinal
cholesterol absorption, ultimately resulting in signiﬁcantly
reduced serum low density lipoprotein (LDL) cholesterol
concentrations at a recommended daily intakes of 2.0–2.5 g
[1–3]. Based on our meta-analysis [4], we recently sug-
gested that plant stanol esters might also lower serum tri-
acylglycerol (TAG) concentrations. These effects were in
particular evident in subjects with elevated TAG baseline
concentrations. This hypothesis was conﬁrmed in a double-
blind placebo-controlled intervention trial in subjects with
the metabolic syndrome, who are characterised by elevated
circulating TAG concentrations [5]. However, an explana-
tion for the observed reduction in serum TAG concentra-
tions is missing. Therefore, we monitored changes in serum
lipoprotein proﬁles via nuclear magnetic resonance (NMR)
analysis obtained in serum samples from the metabolic
syndrome subjects. This NMR approach measures con-
centrations of the different lipoprotein subpopulations
large-, medium- and small-VLDL, IDL, large-, small-,
medium small- and very-small-LDL, large-, medium- and
small-HDL. Large VLDL particles are further called
VLDL-1 particles. In addition, VLDL-, LDL-, and HDL-
size are calculated. This knowledge could provide new
leads concerning effects of plan stanol esters on lipid and
lipoprotein metabolism. For comparison, these parameters
were also analysed in serum samples from another
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normolipidemic subjects in which no effects of plant stanol
esters consumption on serum TAG concentrations were
found [6].
Methods
Study 1: Metabolic Syndrome Subjects,
Diets and Design
Subject characteristics of this study have been reported
before [5]. In short, we included 18 subjects, who had the
metabolic syndrome according to the ATP III criteria [7].
All subjects gave their written informed consent before the
start of the study. The study was approved by the medical
ethical committee of Maastricht University. During a
3-week run-in period, all subjects were instructed to con-
sume with the meals (lunch or diner, but not breakfast) a
low-fat yogurt drink (Emmi, Lucerne, Swiss) containing no
plant stanol esters. At the beginning of the experimental
period, subjects were randomly allocated to one of the two
treatment groups, stratiﬁed for gender and age. Baseline
characteristics of the groups are listed in Table 1. The
control group continued to use the placebo yogurt drink for
another 8 weeks, while a second group used the same low-
fat yogurt drink to which a vegetable oil based stanol ester
mixture was added. Daily intake of plant stanols was 2 g
provided as a one-shot yogurt drink. All products were
coded with a coloured label to blind the subjects and the
investigators.
Study 2: Normolipidemic Subjects, Diets and Design
As described earlier [6], 112 non-hypercholesterolemic
apparently healthy subjects participated in a double-blind
placebo-controlled trial in which we compared the effects
of vegetable oil based and pine-wood based plant stanol
esters versus placebo. In brief, during a 4-week run-in
period subjects were instructed to use margarines and
shortenings with breakfast, lunch and for the preparation of
dinner. At the beginning of the experimental period, sub-
jects were randomly allocated to one of the three treatment
groups, stratiﬁed for gender and age. Since there were no
differences between the two plant stanol ester sources in
their effects on cholesterol metabolism [6, 8, 9], the veg-
etable-oil based and pine-wood based groups were com-
bined into one plant stanol ester group for further analysis.
For the current analysis, we randomly selected 25 subjects
form the control and 25 subjects from each plant stanol
ester group, hereby taking gender distributions into
account. Baseline characteristics of the control versus the
intervention groups are listed in Table 1. The control group
continued to use the placebo margarines and shortenings
for another 8 weeks, while a second group used the same
margarines and shortenings to which the plant stanol ester
mixtures were added. Total daily plant stanol intake was
3.8–4.1 g/day, which is higher than the currently recom-
mended intake. All products were coded with a coloured
label to blind the subjects and the investigators. As in study
1, all subjects gave their written informed consent before
the start of the study, and the study was approved by the
medical ethical committee of Maastricht University.
Table 1 Baseline population characteristics of metabolic syndrome (study 1) and normolipidemic (study 2) subjects
Metabolic syndrome subjects Normolipidemic subjects
Controls (N = 9) Plant stanols (N = 9) Controls (N = 25) Plant stanols (N = 50)
Age (years) 60 ± 76 0 ± 43 5 ± 17 34 ± 15
BMI (kg/m
2) 30.2 ± 1.9 28.1 ± 2.6 23.0 ± 3.2 22.9 ± 3.0
Blood pressure (mm Hg)
Systolic BP 142 ± 14 138 ± 11 119 ± 12 123 ± 12
Diastolic BP 92 ± 10 94 ± 87 4 ± 87 5 ± 8
Serum lipid (mmol/L)
Total cholesterol 6.50 ± 1.59 6.29 ± 1.19 4.81 ± 0.79 5.02 ± 0.69
Non-HDL cholesterol 5.47 ± 1.29 5.32 ± 1.29 – –
LDL cholesterol – – 2.82 ± 0.73 2.89 ± 0.71
HDL cholesterol 1.03 ± 0.26 0.97 ± 0.15 1.61 ± 0.32 1.58 ± 0.39
Triacylglycerol 2.24 ± 1.26 2.21 ± 0.98 0.83 ± 0.34 1.02 ± 0.61
Values are means ± SD. To convert values for total, HDL and LDL cholesterol to mg/dL 9 38.67. To convert values for triacylglycerols to
mg/dL 9 88.54
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Blood Sampling
In both studies, blood samples obtained at the end of the
run-in period and at the end of the 8 weeks experimental
periods, were used for further analysis. All blood sam-
ples were taken after an overnight fast; i.e., subjects
were not allowed to eat and drink (except water) after
10 p.m. in the evening preceding blood sampling, to
drink alcohol the day preceding blood sampling, or to
smoke on the morning of blood sampling. Blood was
sampled into clotting tubes (CORVAC, integrated serum
separator tube, Sherwood Medical Company, St. Louis,
USA). Serum was obtained by centrifugation of the
clotting tubes at 2,0009g for 30 min at 4 C, minimally
1 h after venipuncture. All serum samples were imme-
diately stored in small portions, snap-frozen, and stored
at -80 C until further analysis.
Lipids, Lipoproteins and Lipoprotein Proﬁles
Serum lipids and lipoproteins were analysed as described
[5]. All samples from one subject were analysed within the
same run at the end of the study. In study 1, we reported
serum non-HDL cholesterol concentrations instead of
serum LDL cholesterol concentrations because we could
not use the Friedewald equation to calculate serum LDL
cholesterol, because of the increased serum TAG concen-
trations of our population. Lipoprotein proﬁles at the end of
the run-in period and at the end of the 8 week intervention
period were evaluated by NMR (Liposcience, Raleigh,
USA). Before NMR analysis, two blood samples at the end
of the run-in period and at the end of the experimental
period (at least three and maximally 7 days between both
blood sampling moments) were pooled to minimise the
noise due to normal day-to-day variation in lipoprotein
particle concentrations. Although the two intervention
studies were performed 8 years apart, all NMR analysis
were performed in samples stored at -80 C in retrospect
for both studies at the same time.
Statistics
Changes for all parameters were calculated for each subject
as the difference between values of the intervention period
and run-in periods and reported as means ± SD. The dif-
ferences in changes between the groups were tested with an
unpaired t test in which a P\0.05 was considered sig-
niﬁcant. All statistical analyses were performed with
Statview 4.5.
Results and Discussion
Serum Lipid and Lipoproteins
In both studies, plant stanol ester consumption improved
serum lipoprotein proﬁles. Compared with the control
group, consumption of plant stanol esters for 8 weeks
lowered serum non-HDL cholesterol concentrations by
0.73 ± 0.52 mmol/L or 13.8% (P = 0.012) in the meta-
bolic syndrome subjects. In addition, plant stanol esters
lowered TAG concentrations by 0.23 ± 0.36 mmol/L or
27.5% (P = 0.044). No effects on serum HDL cholesterol
concentrations were found.
In normolipidemic subjects, plant stanol esters also sig-
niﬁcantly lowered serum LDL cholesterol concentrations.
Compared with the control group, this decrease was
0.44 ± 0.29 mmol/L or 13.7% (P\0.001) for the plant
stanol ester group. There were no effects on serum TAG and
HDL cholesterol concentrations. The ﬁnding that serum
TAG concentrations were unchanged in this study is in line
with all other studies in normolipidemic subjects [1].
We now aim to ﬁnd an explanation for the observed
effects on serum TAG concentrations and here postulate the
hypothesis that the TAG lowering effect of plant stanol
esters originates from a reduced hepatic production of large
TAG-rich VLDL-1 particles. We had earlier excluded that
the effects of plant stanol ester consumption on serum TAG
concentrations could be explained by changes in serum
apoCII and apoCIII concentrations, which are both deter-
minants of lipoprotein lipase (LPL) activity [5]. In line with
the unaffected HDL cholesterol concentrations, we have
also shown that CETP activity was not changed [5]. The
hypothesis postulating effects on hepatic VLDL-1 produc-
tion is based on the present ﬁnding that in metabolic syn-
drome subjects plant stanol esters signiﬁcantly reduced
concentrations of large ([60 nm) and medium (35–60 nm)
VLDL particles, as compared to the control group. We are
aware of the fact that we did not measure hepatic VLDL
particle production and VLDL kinetics (i.e., referring to
LPL activity) by using stable isotope approaches. Therefore
it remains speculative whether the suggested hypothetical
mechanism is correct. No effects were found on small
(27–35 nm) VLDL particles or any of the other lipoprotein
fractions (Table 2). The fact that there was no change in the
number of small sized LDL particles was somewhat
unexpected, since the large VLDL-1 particles—of which
the numbers were strongly reduced after plant stanol ester
consumption—are precursors for the smaller denser LDL
particles. This might also imply that the effects on VLDL-1
concentrations are not caused by a reduced hepatic VLDL-1
production.
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tion in the number of large VLDL-1 particles (Table 2)i n
serum from the plant stanol ester group, as compared to
controls. The reduction was however, smaller as compared
to the reduction observed in subjects with the metabolic
syndrome, which is in line with the lack of effects on serum
TAG concentrations. There are however, substantial dif-
ferences between both studies (i.e., plant stanol intake, age,
etc.) not allowing a direct comparison between the out-
comes from both studies.
Assuming that plant stanol esters lower hepatic VLDL-1
production in humans, the mechanism underlying this
effect is still open. In this respect, Ikeda et al. [11] have
recently shown that campest-5-en-3-one (campestenone),
an oxidised derivative of campesterol, was a potent hepatic
PPARalpha activator in mice. Consumption of this plant
Table 2 Effects of plant stanol esters on lipoprotein particle concentrations in metabolic syndrome (study 1) and normolipidemic (study 2)
subjects
Metabolic syndrome subjects Normolipidemic subjects
Controls (N = 9) Plant stanols (N = 9) Controls (N = 25) Plant stanols (N = 50)
Large VLDL particles,[60 nm (nmol/L)
Run-in 5.9 ± 7.1 6.7 ± 8.2 1.9 ± 1.6 2.5 ± 4.1
Test period 8.1 ± 6.8 2.9 ± 3.2 2.0 ± 2.1 1.8 ± 2.8
Change 2.2 ± 5.1 -3.8 ± 6.7
a 0.1 ± 2.7 -0.7 ± 3.1
a
Medium VLDL particles, 35–60 nm (nmol/L)
Run-in 33.4 ± 21.5 36.6 ± 20.9 21.8 ± 10.6 22.7 ± 10.6
Test period 39.2 ± 20.8 27.5 ± 17.8 20.3 ± 12.1 22.0 ± 14.7
Change 5.8 ± 17.5 -9.1 ± 17.7
a -1.5 ± 15.5 -0.7 ± 17.3
Small VLDL particles, 27–35 nm (nmol/L)
Run-in 54.3 ± 14.8 53.6 ± 13.8 41.4 ± 11.6 44.9 ± 17.4
Test period 51.9 ± 17.1 55.5 ± 20.7 35.3 ± 11.9 38.1 ± 19.2
Change -2.5 ± 9.9 1.9 ± 17.6 -6.1 ± 13.7 -6.8 ± 23.1
IDL particles, 23–27 nm (nmol/L)
Run-in 107.9 ± 68.4 76.3 ± 72.4 27.0 ± 25.9 49.4 ± 48.5
Test period 107.7 ± 80.1 84.0 ± 54.0 35.8 ± 35.1 36.3 ± 35.5
Change -0.2 ± 45.1 7.6 ± 54.3 8.7 ± 50.5 -13.1 ± 48.9
a
Large LDL particles, 21.2–23 nm (nmol/L)
Run-in 358 ± 154 416 ± 285 378 ± 115 388 ± 131
Test period 248 ± 210 348 ± 167 351 ± 87 372 ± 116
Change -110 ± 192 -69 ± 213 -26 ± 133 -16 ± 155
Small LDL particles, 18–21.2 nm (nmol/L)
Run-in 1,303 ± 633 1,319 ± 456 521 ± 195 589 ± 328
Test period 1,449 ± 652 1,388 ± 363 548 ± 214 567 ± 326
Change 146 ± 315 68 ± 338 27 ± 279 -22 ± 411
Large HDL particles, 8.8–13 nm (lmol/L)
Run-in 3.7 ± 2.0 5.0 ± 2.3 7.7 ± 2.6 8.3 ± 3.9
Test period 3.6 ± 2.0 5.2 ± 1.7 7.8 ± 2.9 8.2 ± 3.5
Change -0.1 ± 1.2 0.3 ± 2.7 0.1 ± 3.9 -0.2 ± 3.7
Medium HDL particles 8.2–8.8 nm (lmol/L)
Run-in 4.1 ± 3.3 2.8 ± 3.0 3.2 ± 2.4 3.7 ± 3.0
Test period 3.9 ± 3.4 2.7 ± 3.3 3.2 ± 2.4 4.4 ± 3.5
Change -0.2 ± 1.8 -0.1 ± 3.7 -0.0 ± 3.9 0.6 ± 3.7
Small HDL particles, 7.3–8.2 nm (lmol/L)
Run-in 23.6 ± 2.4 21.8 ± 2.7 21.3 ± 3.8 19.5 ± 4.8
Test period 23.8 ± 2.7 22.6 ± 3.4 20.6 ± 5.5 20.2 ± 4.7
Change 0.2 ± 2.0 0.8 ± 2.6 -0.7 ± 6.6 0.6 ± 5.0
Values are means ± SD
a P\0.05 versus control
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123sterol derivative resulted in a lower concentration of TAG
in serum and liver. These changes in mice ﬁt very well with
our suggestion of a lowered hepatic large TAG-rich VLDL
particle production after plant stanol ester consumption.
However, in our studies we provided plant stanol esters and
not plant sterol esters. This introduces the question whether
intermediates with similar effects can be formed from plant
stanol esters in vivo in humans.
In apoE*3-Leiden mice, Volger et al. [10] have shown
that plant stanol ester consumption lowered hepatic TAG
(-38%), free cholesterol (-31%), and cholesterol ester
(-62%) content. Since hepatic TAG concentrations are
thought to be a driving force behind large sized VLDL
particle production—at least in humans—[12], the
observed reduction in hepatic TAG in these mice suggest
that the number of larger sized VLDL particles was prob-
ably lowered. However, only cholesterol incorporation into
nascent VLDL particles was lowered, while total VLDL-
TAG and total VLDL-apoB production rates were sur-
prisingly unchanged. Unfortunately, VLDL production
rates of the different VLDL-particle subpopulations were
not measured.
This data also introduces a ﬁnal discussion point: the
functional consequences of a lowered VLDL-1 production.
In humans, it is generally recognised that the amount of fat
in the liver is an important factor determining hepatic
VLDL-1 production [12]. Therefore, the lowered hepatic
VLDL-1 production may indicate a reduced ectopic fat
accumulation in the liver. If this is indeed true, plant stanol
ester consumption may be even more beneﬁcial than cur-
rently anticipated. This latter assumption warrants, how-
ever, further study.
In conclusion, we have earlier reported that plant stanol
esters not only lower serum LDL cholesterol concentra-
tions, but also serum TAG concentrations in subjects with
elevated TAG concentrations at baseline. We here present
data supporting the hypothesis that the effect is caused by a
reduction in the hepatic production of large TAG-rich
VLDL-1 particles. Effects are most pronounced in meta-
bolic syndrome subjects, resulting in subsequent reductions
in serum TAG concentrations.
Acknowledgments We are indebted to the members of our dietary
and technical staff, and to all volunteers for their cooperation and
interest. The studies were sponsored by RAISIO Life Sciences,
Raisio, Finland (study 2), and McNeil, UK (study 1).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Demonty I, Ras RT, van der Knaap HCM, Duchateau GSMJE,
Meijer L, Zock PL, Gelijnse JM, Trautwein EA (2009) Contin-
uous dose–response relationship of the LDL cholesterol lowering
effect of phytosterol intake. J Nutr 139:271–284
2. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R
(2003) Efﬁcacy and safety of plant stanols and sterols in the
management of blood cholesterol levels. Mayo Clin Proc
78:965–978
3. Chan YM, Varady KA, Lin Y, Trautwein E, Mensink RP, Plat J,
Jones PJ (2006) Plasma concentrations of plant sterols: physiol-
ogy and relationship with coronary heart disease. Nutr Rev
64:385–402
4. Naumann E, Plat J, Kester ADM, Mensink RP (2008) The
baseline serum lipoprotein proﬁle is related to plant stanol
induced changes in serum lipids and lipoproteins. J Am Coll Nutr
27:117–126
5. Plat J, Brufau G, Dallingha-Thie GM, Dasselaar M, Mensink RP
(2009) A plant stanol yogurt drink alone or combined with a low-
dose statin lowers serum triacylglycerol and non-HDL cholesterol
in metabolic syndrome patients. J Nutr 139:1143–1149
6. Plat J, Mensink RP (2000) Vegetable oil based versus wood based
stanol ester mixtures: effects on serum lipids and hemostatic
factors in non hypercholesterolemic subjects. Athersclerosis
148:101–112
7. Grundy SM (2001) United States cholesterol guidelines 2001:
expanded scope of intensive low-density lipoprotein-lowering
therapy. Am J Cardiol 88:23J–27J
8. Plat J, Mensink RP (2001) Effects of diets enriched with two
different plant stanol ester mixtures on plasma ubiquinol-10 and
fat-soluble antioxidant concentrations. Metabolism 50:520–529
9. Plat J, Mensink RP (2001) Effects of plant stanol esters on LDL
receptor protein expression and on LDL receptor and HMG-CoA
reductase mRNA expression in mononuclear blood cells of
healthy men and women. FASEB J 16:258–260
10. Volger OL, van der Boom J, de Wit ECM, van Duyvenvoorde W,
Hornstra G, Plat J, Havekes LM, Mensink RP, Princen HMG
(2001) Dietary plant stanol esters reduce VLDL-cholesterol
secretion and bile saturation in apoE*3-Leiden transgenic mice.
Artherioscler Thromb Vasc Biol 21:1046–1052
11. Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T,
Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y,
Tomoyori H, Imaizumi K, Suzuki K (2006) Campest-5-en-3-one,
an oxidized derivative of campesterol, activates PPARalpha,
promotes energy consumption and reduces visceral fat deposition
in rats. Biochim Biophys Acta 1760:800–807
12. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen
A, Westerbacka J, Vehkavaara S, Ha ¨kkinen A, Olofsson SO,
Yki-Ja ¨rvinen H, Bore ´n J (2006) Overproduction of large VLDL
particles is driven by increased liver fat content in man.
Diabetologia 49:755–765
Lipids (2009) 44:1149–1153 1153
123